Pfizer Inc. PFE announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin for the treatment of pulmonary arterial hypertension in regions where it is approved.
In addition, Pfizer is discontinuing clinical studies of Thelin worldwide.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
